Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metamin 3D
- Development stage
- Unknown
- Lead developer
- Standard Chem & Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Metamin 3D is a fixed-dose combination (FDC) therapy comprising metformin, atorvastatin, and aspirin. It is specifically designed to manage metabolic syndrome by simultaneously addressing its key components: hyperglycemia, dyslipidemia, and prothrombotic risk. Metformin, a biguanide antihyperglycemic, works primarily by activating AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity. Atorvastatin, an HMG-CoA reductase inhibitor, lowers low-density lipoprotein (LDL) cholesterol levels. Aspirin provides antiplatelet effects through the inhibition of cyclooxygenase enzymes, reducing cardiovascular risk. This combination aims to simplify complex treatment regimens and improve patient adherence. Metamin 3D was developed and manufactured by Standard Chem & Pharm and has been evaluated in Phase 3 clinical trials in Taiwan, notably at Taichung Veterans General Hospital.
- Brand names
- Metamin 3DMetamin3DMetamin-3D
- Other names
- metformin + atorvastatin + aspirin
02
Targets
KATP channel (ATP-sensitive potassium channel)PPARA (Peroxisome proliferator-activated receptor alpha)ND1 (Mitochondrial electron transport chain complex I)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on Metamin 3D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metamin 3D.